Javier Palazuelos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Javier Palazuelos has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Tania Aguado
Complutense University
15 shared publications - Ismael Galve-Roperh
Department of Biochemistry and Molecular Biology, Instituto Universitario de Investigación Neuroquímica (IUIN), Complutense University, Madrid, Spain
14 shared publications - Manuel Guzmán
Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Complutense University of Madrid, Madrid, Spain
14 shared publications Beat Lutz
Institute of Physiological Chemistry, University Medical Center Mainz, Mainz, Germany
8 shared publicationsKrisztina Monory
Institute of Physiological Chemistry, University Medical Center Mainz, Mainz, Germany
7 shared publicationsManuel Guzmán
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
6 shared publications
Latest Publications
- Open Access
Neuronal Aralar/AGC1 deficiency impairs social behavior through dopaminergic and redox dysfunction and is rescued by β-hydroxybutyrate
Background: Pathogenic variants in SLC25A12/AGC1 (Aralar) have been linked to autism spectrum disorder (ASD), yet the mechanisms connecting neuronal metabolic dysfunction to altered social behavior remain poorly understood. Aralar is a key component of the malate-aspartate shuttle, supporting neuronal oxidative metabolism and lactate utilization. Here, we investigated the consequences of postnatal neuronal Aralar deletion and the therapeutic potential of β-hydroxybutyrate (BHB). Methods: We generated neuron-specific Aralar knockout mice (Neu Aralar-KO) using CamKIIα-Cre, producing efficient recombination in cortex, hippocampus, and striatum. Behavioral, transcriptomic, neurochemical, morphometric, histological, and biochemical analyses were performed in adult mice. The effects of systemic BHB administration were assessed using behavioral, metabolic, oxidative stress, and transcriptomic endpoints. Results: Despite a 55-65% reduction of Aralar expression in forebrain regions, Neu Aralar-KO mice displayed normal growth, survival, brain structure, and myelination. Unexpectedly, loss of neuronal Aralar did not impair spatial memory, episodic memory, or reversal learning. In contrast, Neu Aralar-KO mice exhibited hyperactivity and a marked deficit in sociability, revealing an ASD-relevant behavioral phenotype. Morphological analysis showed significant remodeling of striatal dendritic spines without changes in spine density. Transcriptomic profiling identified 433 differentially expressed genes, the vast majority being upregulated, with enrichment of pathways related to neuropeptide signaling, synaptic transmission, membrane excitability, and behavior. Notably, genes involved in dopamine (DA) and glutamate handling, synaptic connectivity, neuromodulatory signaling, and ASD-associated pathways were strongly induced. Neurochemical analyses revealed preserved glutamate and GABA levels but reduced striatal DA content accompanied by an increased DOPAC/DA ratio, indicating enhanced DA degradation. DAergic neurons of the ventral tegmental area (VTA) showed minimal recombination, suggesting that DA dysfunction arises through non-cell-autonomous mechanisms. Consistent with increased DA oxidative catabolism, Neu Aralar-KO striata displayed elevated lipid peroxidation, induction of glutathione-related pathways, upregulation of antioxidant genes, and astrocyte activation. Remarkably, BHB treatment restored sociability, normalized striatal metabolic alterations, reduced oxidative stress, and abolished genotype-dependent neurochemical abnormalities. Transcriptomic analyses further revealed that Aralar deficiency recapitulates a substantial fraction of the fasting/BHB-induced epigenetic transcriptional program. Conclusions: Postnatal neuronal Aralar deficiency uncouples social behavior from cognitive performance and drives ASD-like phenotypes through a mechanism linking neuronal metabolic dysfunction, oxidative stress, glial activation, and impaired DAergic homeostasis. The rescue of behavioral, metabolic, and redox abnormalities by BHB identifies restoration of metabolic homeostasis as a major therapeutic mechanism and highlights metabolic interventions as promising strategies for AGC1 deficiency and ASD-associated disorders involving neuronal metabolic dysfunction.
Open AccessNeuronal Aralar/AGC1 deficiency impairs social behavior through dopaminergic and redox dysfunction and is rescued by β-hydroxybutyrate
Background: Pathogenic variants in SLC25A12/AGC1 (Aralar) have been linked to autism spectrum disorder (ASD), yet the mechanisms connecting neuronal metabolic dysfunction to altered social behavior remain poorly understood. Aralar is a key component of the malate-aspartate shuttle, supporting neuronal oxidative metabolism and lactate utilization. Here, we investigated the consequences of postnatal neuronal Aralar deletion and the therapeutic potential of β-hydroxybutyrate (BHB). Methods: We generated neuron-specific Aralar knockout mice (Neu Aralar-KO) using CamKIIα-Cre, producing efficient recombination in cortex, hippocampus, and striatum. Behavioral, transcriptomic, neurochemical, morphometric, histological, and biochemical analyses were performed in adult mice. The effects of systemic BHB administration were assessed using behavioral, metabolic, oxidative stress, and transcriptomic endpoints. Results: Despite a 55-65% reduction of Aralar expression in forebrain regions, Neu Aralar-KO mice displayed normal growth, survival, brain structure, and myelination. Unexpectedly, loss of neuronal Aralar did not impair spatial memory, episodic memory, or reversal learning. In contrast, Neu Aralar-KO mice exhibited hyperactivity and a marked deficit in sociability, revealing an ASD-relevant behavioral phenotype. Morphological analysis showed significant remodeling of striatal dendritic spines without changes in spine density. Transcriptomic profiling identified 433 differentially expressed genes, the vast majority being upregulated, with enrichment of pathways related to neuropeptide signaling, synaptic transmission, membrane excitability, and behavior. Notably, genes involved in dopamine (DA) and glutamate handling, synaptic connectivity, neuromodulatory signaling, and ASD-associated pathways were strongly induced. Neurochemical analyses revealed preserved glutamate and GABA levels but reduced striatal DA content accompanied by an increased DOPAC/DA ratio, indicating enhanced DA degradation. DAergic neurons of the ventral tegmental area (VTA) showed minimal recombination, suggesting that DA dysfunction arises through non-cell-autonomous mechanisms. Consistent with increased DA oxidative catabolism, Neu Aralar-KO striata displayed elevated lipid peroxidation, induction of glutathione-related pathways, upregulation of antioxidant genes, and astrocyte activation. Remarkably, BHB treatment restored sociability, normalized striatal metabolic alterations, reduced oxidative stress, and abolished genotype-dependent neurochemical abnormalities. Transcriptomic analyses further revealed that Aralar deficiency recapitulates a substantial fraction of the fasting/BHB-induced epigenetic transcriptional program. Conclusions: Postnatal neuronal Aralar deficiency uncouples social behavior from cognitive performance and drives ASD-like phenotypes through a mechanism linking neuronal metabolic dysfunction, oxidative stress, glial activation, and impaired DAergic homeostasis. The rescue of behavioral, metabolic, and redox abnormalities by BHB identifies restoration of metabolic homeostasis as a major therapeutic mechanism and highlights metabolic interventions as promising strategies for AGC1 deficiency and ASD-associated disorders involving neuronal metabolic dysfunction.
- Open Access
- 9 April 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Cannabinoid CB1 receptors drive oligodendrocyte maturation during myelin regeneration
Oligodendrocytes, the myelin-producing cells in the central nervous system, derive from oligodendrocyte progenitor cells during both development and remyel
- 9 April 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessCannabinoid CB1 receptors drive oligodendrocyte maturation during myelin regeneration
Oligodendrocytes, the myelin-producing cells in the central nervous system, derive from oligodendrocyte progenitor cells during both development and remyel
- 9 November 2024
- Published by Elsevier in Progress in Neurobiology
- Vol. 243, 102683
CB1 receptors in NG2 cells mediate cannabinoid-evoked functional myelin regeneration
- 9 November 2024
- Published by Elsevier in Progress in Neurobiology
- Vol. 243, 102683
CB1 receptors in NG2 cells mediate cannabinoid-evoked functional myelin regeneration
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S202
NG2 CELLS MEDIATE CANNABINOID-INDUCED FUNCTIONAL RECOVERY FOLLOWING DEMYELINATION
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S202
Open AccessNG2 CELLS MEDIATE CANNABINOID-INDUCED FUNCTIONAL RECOVERY FOLLOWING DEMYELINATION
- Open Access
- 7 July 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (7) , 1-13
Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice
Cannabinoids are known to modulate oligodendrogenesis and developmental CNS myelination. However, the cell-autonomous action of these compounds on oligodendroglial cells in vivo, and the molecular mechanisms underlying these effects have not yet been studied. Here, by using oligodendroglial precursor cell (OPC)-targeted genetic mouse models, we show that cannabinoid CB1 receptors exert an essential role in modulating OPC differentiation at the critical periods of postnatal myelination. We found that selective genetic inactivation of CB1 receptors in OPCs in vivo perturbs oligodendrogenesis and postnatal myelination by altering the RhoA/ROCK signaling pathway, leading to hypomyelination, and motor and cognitive alterations in young adult mice. Conversely, pharmacological CB1 receptor activation, by inducing E3 ubiquitin ligase-dependent RhoA proteasomal degradation, promotes oligodendrocyte development and CNS myelination in OPCs, an effect that was not evident in OPC-specific CB1 receptor-deficient mice. Moreover, pharmacological inactivation of ROCK in vivo overcomes the defects in oligodendrogenesis and CNS myelination, and behavioral alterations found in OPC-specific CB1 receptor-deficient mice. Overall, this study supports a cell-autonomous role for CB1 receptors in modulating oligodendrogenesis in vivo, which may have a profound impact on the scientific knowledge and therapeutic manipulation of CNS myelination by cannabinoids.
- 7 July 2022
- Published by Springer Nature in Cell Death & Disease
- Vol. 13 (7) , 1-13
Open AccessCannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice
Cannabinoids are known to modulate oligodendrogenesis and developmental CNS myelination. However, the cell-autonomous action of these compounds on oligodendroglial cells in vivo, and the molecular mechanisms underlying these effects have not yet been studied. Here, by using oligodendroglial precursor cell (OPC)-targeted genetic mouse models, we show that cannabinoid CB1 receptors exert an essential role in modulating OPC differentiation at the critical periods of postnatal myelination. We found that selective genetic inactivation of CB1 receptors in OPCs in vivo perturbs oligodendrogenesis and postnatal myelination by altering the RhoA/ROCK signaling pathway, leading to hypomyelination, and motor and cognitive alterations in young adult mice. Conversely, pharmacological CB1 receptor activation, by inducing E3 ubiquitin ligase-dependent RhoA proteasomal degradation, promotes oligodendrocyte development and CNS myelination in OPCs, an effect that was not evident in OPC-specific CB1 receptor-deficient mice. Moreover, pharmacological inactivation of ROCK in vivo overcomes the defects in oligodendrogenesis and CNS myelination, and behavioral alterations found in OPC-specific CB1 receptor-deficient mice. Overall, this study supports a cell-autonomous role for CB1 receptors in modulating oligodendrogenesis in vivo, which may have a profound impact on the scientific knowledge and therapeutic manipulation of CNS myelination by cannabinoids.
- Open Access
- 3 July 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (20) , 4176-4192
Δ9‐Tetrahydrocannabinol promotes functional remyelination in the mouse brain
Background and purpose Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.
- 3 July 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (20) , 4176-4192
Open AccessΔ9‐Tetrahydrocannabinol promotes functional remyelination in the mouse brain
Background and purpose Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.
- Open Access
- 15 March 2021
- Published by Springer Nature in Research Square
Δ 9 -Tetrahydrocannabinol Promotes Functional Remyelination in the Mouse Brain
Background: Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Methods: By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Results: We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions: Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.
- 15 March 2021
- Published by Springer Nature in Research Square
Open AccessΔ 9 -Tetrahydrocannabinol Promotes Functional Remyelination in the Mouse Brain
Background: Research on demyelinating disorders aims to find novel molecules able to induce oligodendrocyte precursor cell differentiation to promote CNS remyelination and functional recovery. Δ9-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination. However, the possible effect of THC on myelin repair has never been studied. Methods: By using oligodendroglia-specific reporter mouse lines in combination with 2 models of toxin-induced demyelination, we analyzed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination. Results: We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination, and motor function recovery. THC also promoted axonal remyelination in organotypic cerebellar cultures. THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation. Conclusions: Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.
- Open Access
Cover Image, Volume 69, Issue 3
Open AccessCover Image, Volume 69, Issue 3
- Open Access
Δ9‐Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo
Δ9‐Tetrahydrocannabinol (THC), the main bioactive compound found in the plant Cannabis sativa, exerts its effects by activating cannabinoid receptors present in many neural cells. Cannabinoid receptors are also physiologically engaged by endogenous cannabinoid compounds, the so‐called endocannabinoids. Specifically, the endocannabinoid 2‐arachidonoylglycerol has been highlighted as an important modulator of oligodendrocyte (OL) development at embryonic stages and in animal models of demyelination. However, the potential impact of THC exposure on OL lineage progression during the critical periods of postnatal myelination has never been explored. Here, we show that acute THC administration at early postnatal ages in mice enhanced OL development and CNS myelination in the subcortical white matter by promoting oligodendrocyte precursor cell cycle exit and differentiation. Mechanistically, THC‐induced‐myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists. Moreover, the THC‐mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects. Our study identifies THC as an effective pharmacological strategy to enhance oligodendrogenesis and CNS myelination in vivo.
Open AccessΔ9‐Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo
Δ9‐Tetrahydrocannabinol (THC), the main bioactive compound found in the plant Cannabis sativa, exerts its effects by activating cannabinoid receptors present in many neural cells. Cannabinoid receptors are also physiologically engaged by endogenous cannabinoid compounds, the so‐called endocannabinoids. Specifically, the endocannabinoid 2‐arachidonoylglycerol has been highlighted as an important modulator of oligodendrocyte (OL) development at embryonic stages and in animal models of demyelination. However, the potential impact of THC exposure on OL lineage progression during the critical periods of postnatal myelination has never been explored. Here, we show that acute THC administration at early postnatal ages in mice enhanced OL development and CNS myelination in the subcortical white matter by promoting oligodendrocyte precursor cell cycle exit and differentiation. Mechanistically, THC‐induced‐myelination was mediated by CB1 and CB2 cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists. Moreover, the THC‐mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects. Our study identifies THC as an effective pharmacological strategy to enhance oligodendrogenesis and CNS myelination in vivo.
- 1 November 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 157, 85-96
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders
- 1 November 2018
- Published by Elsevier in Biochemical Pharmacology
- Vol. 157, 85-96
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders